Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Turcot syndrome 1Pancreatic Neoplasms 1Muscle Invasive Bladder Cancer 1Lung Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 5Nivolumab 3durvalumab 2atezolizumab 2relatlimab 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1danvatirsen 1avelumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Irinotecan 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1IMM-101 1E7777 fusion protein 1Docetaxel 1Disulfides 1Diffusion Tensor Imaging 1Cyclophosphamide 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Turcot syndrome × danvatirsen × Clear all
NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
39 enrolled
GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡